What is the mechanism of action of Chuan Lian Zi?

Chuan Lian Zi works primarily through its active compound toosendanin, which exhibits analgesic and antiparasitic properties. In Traditional Chinese Medicine (TCM), it moves liver qi to relieve stagnation and pain. Pharmacologically, toosendanin appears to block neuromuscular transmission in parasites and modulate pain pathways in the central nervous system. While these mechanisms are supported by animal studies, human clinical data remains limited (Evidence Level C), suggesting a dual action on smooth muscle relaxation and parasitic expulsion.

Does Chuan Lian Zi interact with prescription medications?

Yes, Chuan Lian Zi poses significant interaction risks, particularly with hepatotoxic drugs. Because the herb carries a risk of liver toxicity at high doses, combining it with medications known to strain the liver—such as acetaminophen, statins, or certain antibiotics—can compound the risk of liver damage. Additionally, its antiparasitic action may interfere with concurrent antiparasitic therapies. Patients should consult a healthcare provider before combining this herb with prescription medications (Evidence Level C).

What is the standard dosage for Chuan Lian Zi?

The standard adult dosage for Chuan Lian Zi is 3 to 9 grams when prepared as a decoction, or approximately 150 mg for concentrated extracts. Due to the narrow therapeutic window, dosages exceeding 9 grams significantly increase the risk of toxicity. It is crucial to adhere strictly to professional recommendations, as the difference between a therapeutic and toxic dose is relatively small. Dosage may vary based on the specific condition, such as hernia pain versus parasitic infection (Evidence Level C/Traditional).

Is Chuan Lian Zi safe to use during pregnancy?

No, Chuan Lian Zi is contraindicated during pregnancy and is considered unsafe. The herb contains compounds like toosendanin that can stimulate uterine contractions, potentially leading to miscarriage. Furthermore, the herb's potential hepatotoxicity poses risks to both maternal and fetal health. Breastfeeding women and young children should also avoid this herb. Safety data is limited, but traditional usage guidelines and pharmacological evidence strictly advise against its use in these populations (Evidence Level C).

Chuan Lian Zi (Melia toosendan)

PubMed-compiled information sheet

This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.

Compiled from 30 PubMed articles · model: gemma4:31b

Summary

Chuan Lian Zi (Melia toosendan) is a medicinal plant containing the bioactive triterpenoid toosendanin, which exhibits anti-tumor, immunosuppressive, and anti-parasitic activities [PMID:36395606, PMID:37738795].

Background

Melia toosendan Sieb. et Zucc. is a plant of the Meliaceae family [PMID:32794175]. Its dried mature fruit is known as Fructus Meliae Toosendan (FMT) [PMID:36395606].

Traditional uses

Traditionally employed in Chinese and Korean herbal medicine for relieving pain, treating roundworms (ascariasis), and as an anthelmintic [PMID:37896213, PMID:40049104, PMID:34637887].

Active compounds

The primary bioactive marker is toosendanin (TSN), a tetranortriterpenoid limonoid [PMID:32794175, PMID:39428181]. Other constituents include various limonoids (e.g., neoazedarachins A, B, D, toosendanal, 12-O-methylvolkensin), tirucallane-type triterpenoids, and unsaturated fatty acids [PMID:27315928, PMID:10389275, PMID:37244502, PMID:34637887].

Mechanism of action

Toosendanin (TSN) acts through multiple pathways: it reprograms macrophages by interacting with Hck and Lyn to reverse immunosuppression in glioblastoma [PMID:36791206]; inhibits T-cell proliferation via the P38 MAPK signaling pathway [PMID:38588767]; induces apoptosis in various cancer cells via mitochondrial pathways [PMID:31115 la, PMID:20157879] or the BNIP3/AMPK pathway [PMID:38773915]; and triggers ferroptosis in hepatocellular carcinoma via WWOX-mediated p53/SAT1 and NRF2/FPN1 axes [PMID:39894307]. It also blocks the STING signaling pathway by inhibiting LYN kinase and STING protein to alleviate ulcerative colitis [PMID:41187884].

Clinical evidence

Evidence DHepatocellular Carcinoma

Crude extract and purified toosendanin inhibited cancer cell growth in vitro and in vivo (mouse models) [PMID:26383159, PMID:20157879].

Evidence DGlioblastoma

Toosendanin reversed macrophage-mediated immunosuppression and, in combination with immune checkpoint blockade, induced regression of syngeneic tumors in mice [PMID:36791206].

Evidence DUlcerative Colitis

Toosendanin ameliorates ulcerative colitis by suppressing STING-dependent genes and phosphorylation of STING [PMID:41187884].

Evidence DCerebral Ischemia/Reperfusion Injury

Post-stroke administration of toosendanin reduced infarct volume and improved outcomes in MCAO mice by inhibiting neural ferroptosis [PMID:42216494].

Evidence DOsteoporosis

Toosendanin inhibits the differentiation of osteoclast precursors induced by RANKL [PMID:37896213].

Evidence DLung Squamous Cell Carcinoma

Drug interactions

Toosendanin significantly alters the pharmacokinetic profile of tamoxifen, resulting in a dose-dependent increase in the maximum plasma concentration of tamoxifen in rats [PMID:41433211].

Evidence summary

The current evidence is primarily based on in vitro studies and animal models (Level D). While there is strong preclinical evidence for anti-cancer and anti-inflammatory effects, significant hepatotoxicity is noted, and clinical research data in humans is lacking [PMID:35140606].

PubMed sources

1.PMID: 36791206 (2023) — Small-molecule toosendanin reverses macrophage-mediated immunosuppression to overcome glioblastoma resistance to immunotherapy. · Science translational medicine
2.PMID: 39099169 (2024) — Preserving mitochondrial homeostasis protects against drug-induced liver injury via inducing OPTN (optineurin)-dependent Mitophagy. · Autophagy
3.PMID: 32794175 (2020) — Characterization of a 2,3-oxidosqualene cyclase in the toosendanin biosynthetic pathway of Melia toosendan. · Physiologia plantarum
4.PMID: 27315928 (1998) — New Limonoids from Melia toosendan. · Bioscience, biotechnology, and biochemistry
5.PMID: 38588767 (2024) — Toosendanin inhibits T-cell proliferation through the P38 MAPK signalling pathway.

Chuan Lian Zi

Sources & Citations